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Abstract
Background: Screening for abdominal aortic aneurysm (AAA) of men aged 65-74 years reduces the AAA-related 
mortality and is generally considered cost effective. Despite of this only a few national health care services have 
implemented permanent programs.
Around 10% of men in this group have peripheral arterial disease (PAD) defined by an ankle brachial systolic blood 
pressure index (ABI) below 0.9 resulting in an increased mortality-rate of 25-30%. In addition well-documented health 
benefits may be achieved through primary prophylaxis by initiating systematic cholesterol-lowering, smoking 
cessation, low-dose acetylsalicylic acid (aspirins), exercise, a healthy diet and blood-pressure control altogether 
reducing the increased risks for cardiovascular disease by at least 20-25%.
The benefits of combining screening for AAA and PAD seem evident; yet they remain to be established. The objective 
of this study is to assess the efficacy and the cost-effectiveness of a combined screening program for AAA, PAD and 
hypertension.
Methods: The Viborg Vascular (VIVA) screening trial is a randomized, clinically controlled study designed to evaluate 
the benefits of vascular screening and modern vascular prophylaxis in a population of 50,000 men aged 65-74 years. 
Enrolment started October 2008 and is expected to stop in October 2010. The primary outcome is all-cause mortality. 
The secondary outcomes are cardiovascular mortality, AAA-related mortality, hospital services related to cardiovascular 
conditions, prevalence of AAA, PAD and potentially undiagnosed hypertension, health-related quality of life and cost 
effectiveness. Data analysis by intention to treat.
Results: Major follow-up will be performed at 3, 5 and 10 years and final study result after 15 years.
Trial registration: ClinicalTrials.gov NCT00662480
Background
It has been demonstrated that abdominal aortic aneu-
rysm (AAA) screening of men aged 65-74 years reduces
AAA mortality. Research at Viborg Hospital published in
the British Medical Journal in March 2005 [1] shows that
only 352 Danish men above the age of 65 require AAA
screening to avoid one AAA rupture-related death in the
subsequent 5-year period. Furthermore, it seems that the
long-term economic efficiency of screening is at a level,
which is generally considered cost effective, at least from
a health care sector perspective [2-4]. Despite the clinical
and economic evidence for the attractiveness of popula-
tion screening, few national health care services have
implemented permanent programs.
The majority of AAAs diagnosed by screening does not
comprise a rupture risk due to being detected early, but
nearly half expand to sizes requiring repair. However
growth may be limited through smoking cessation [5,6],
low-dose aspirin [7-9], statin treatment [10] and ACE
inhibitor therapy [11] which will ultimately also reduce
the increased cardiovascular risk of the affected patients
[12].
International studies indicate that approximately 5-10%
of men above the age of 60 show signs of peripheral arte-
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Page 2 of 6rial disease (PAD; ankle brachial systolic blood pressure
index (ABI) <0.9) - a proportion which increases with age,
and mainly non-symptomatic. Approximately 25-30% of
these men will die from cardiovascular disease within a 5-
year period, and an even higher proportion will need hos-
pitalization due to cardiovascular disease. Cholesterol-
lowering, smoking cessation, low-dose acetylsalicylic acid
(aspirins), exercise, a healthy diet and blood-pressure
control reduce the increased risks for cardiovascular dis-
ease by at least 20-25% [13-16]. So far, screening studies
have neglected the interaction between PAD-screening
and such general prophylactic efforts, and thus the bene-
fit and cost effectiveness of screening may be underesti-
mated.
In sum, well-documented health benefits may be
achieved through prophylactic screening for cardiovascu-
lar disease. Advantages include fewer premature deaths
and a reduction in the number of amputations and hospi-
tal admissions. Furthermore, hospital costs may be
reduced by the decrease in admissions and in-hospital
post-operative care.
The benefits of combining screening for AAA and PAD
thus seem evident; yet they remain to be established. The
objective of this study is to assess the efficacy and the
cost-effectiveness of a combined screening program for
AAA, PAD and hypertension.
Methods
The Viborg Vascular screening program
In the timeframe of October 2008 until October 2010
approximately 50,000 65-74 year-old Danish men will be
randomized to either receive an invitation for vascular
screening or being a control (Figure 1). ABI measure-
ment, ultrasound scan of the aorta in addition to a ques-
tionnaire regarding lifestyle parameters, medical and
smoking status is performed by trained project-nurses in
3 mobile units at local hospitals in the mid region of Jut-
land, Denmark.
In the case of infrarenal aortic dilatation such findings
are; i) pre-aneurysmatic (<24-30 mm<) or ii) aneurys-
matic (≥30 mm). Dilatation <50 mm is controlled annu-
ally with ultrasound scanning and dilatation > 50 mm
referred for consultation by a vascular surgeon. PAD may
be reliable diagnosed with a portable ultrasound Doppler
and blood pressure cuff. PAD is defined as ABI below 0.9
or above 1.4 and annual control is offered. In the case of
suspected undiscovered hypertension (bloodpressure >
160/100) the patient is encouraged to see his family phy-
sician for further assessment and treatment.
During a training course, six project-nurses have been
educated in the natural history of AAA, PAD and hyper-
tension, instruction in life style changes and smoking ces-
sation, blood sampling and bed side cholesterol
measurement and the initiation of antiplatelet and lipid
lowering medication. They were trained under supervi-
sion to measure ABI and perform ultrasound scanning of
the aorta Independent examinations were only allowed,
when the team-interobserver variation of aortic anterior-
posterior diameter were below 2 mm, and ABI below
10%. The nurses operate in three mobile teams which will
each be equipped with uniform portable Dopplers, blood
pressure cuffs and portable ultrasound scanners and per-
form the screening sessions at the hospitals in the region.
The project secretary will continually invite participants
to their regional hospital using the names and address
information from the randomization files.
Participants are informed that they should wear expe-
dient footwear. The letter is accompanied by an option to
refuse or reschedule in writing. Non-responders are re-
invited once. Finally, enclosed with the invitation is a
small questionnaire on smoking habits, anamnesis, walk-
ing-related pain (Walking Impairment Questionnaire),
use of medicine, and the EUROQOL five dimensions
(EQ5D) health questionnaire to obtain psychometric
measures. This has recently been validated in Danish
population norms [17]. Study participants commit to the
program with a written consent using pre-printed con-
sent forms.
To visualise the aorta the ultrasound 4 MHz transducer
is placed longitudinally just above and a little to the left of
the navel. In cases of dilation, the maximal perpendicular
AP diameter is measured. If no dilation is found, the AP
diameter is measured two centimetres above the bifurca-
tion. Simultaneously, peripheral pulse data are recorded
by the other nurse. Brachial blood pressure is automati-
cally measured concurrently with the ankle blood pres-
sure by detecting the Doppler signal from the dorsalis
pedis artery (DPA) and first inflating the blood pressure
cuff until the signal disappears and then deflating the cuff
until the signal reappears. The mean pressure of the two
measurements is recorded, and the same procedure per-
formed for the tibialis posterior artery (TPA). Subse-
quently, the same procedure is repeated in the opposite
extremity.
Follow-up and data collection
All positive findings are subject to clinical monitoring to
provide a reassuring context for the communication of
the finding and its consequences. In the case of PAD the
participant is informed of the relatively positive progno-
sis of leg survival and the need to initiate suitable prophy-
lactic measures including walking/exercise, smoking
cessation, low-fat diet, aspirin and statin treatment. Cho-
lesterol levels are measured. If it exceeds 4.0 mmol/l, cho-
lesterol is unlikely to fall below 3.5 mmol/l following
relevant diet changes and, consequently, the patient is
given a prescription for 40 mg simvastatin/day. Annual
follow-up with ABI measurement is offered. The EQ-5D
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up.
In the case of AAA the aorta is reassessed, the finding is
stored digitally and the calcification degree and mural
thrombus is determined. Information regarding the natu-
ral history of AAA is delivered and the need to initiate
suitable prophylactic measures including exercise, smok-
ing cessation, low-fat diet, aspirin and statin treatment in
Figure 1 Expected flow-chart concerning vascular screening (VIVA) for peripheral arterial disease, abdominal aortic aneurysm and hyper-
tension.
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of Cardiology 2007. If the AAA exceeds a diametre of ≥
50 mm, the patient is referred for CT scan and assess-
ment by a vascular surgeon to further surveillance or sur-
gery. If the AAA is below 5 cm, annual control with
ultrasound scan is offered. The EQ-5D is fulfilled upon
visit and in connection with any follow-up, as well as
annually after AAA surgery.
Data from the screening procedure are collected in a
large database. Information concerning deaths, includ-
ing-date and cause of death, is obtained from the Civil
Registration System. Information on visits to outpatient
clinics and hospital admissions caused by cardiovascular
conditions including amputations is obtained from the
National Patient Registry. From the Danish Causes of
Death Registry, data on cause of death are collected. The
information is classified according to cause; AAA-related
or cardiovascular.
Study population
To maximize the possibility of detecting an effect, men
aged 65-74 are screened, as this group has a high preva-
lence of non-symptomatic cardiovascular disease as well
as a long remaining life expectancy. Screening of men
above the age of 74 presumably would have resulted in
higher prevalences of AAA and PAD, but also a higher
mortality associated with other conditions and a lower
acceptance rate. Similarly, screening of men below the
age of 65 would demonstrate lower mortality, but also a
lower prevalence and a lower rupture frequency. Among
women in the age interval of 65-74, PAD and AAA fre-
quencies are reported to be lower and to occur later in
life; hence screening women would, ceteris paribus, yield
a lower detection rate. Furthermore, as mortality from
other causes is even higher among women as compared
to men, the effect of detecting a case would be inferior. It
should be noted however that the reports of such differ-
ences between genders are old and the extent to which
significant differences persist is uncertain.
As per January 1, 2007 there were approximately 50,000
men aged 65-74 years in the Mid Region of Denmark,
which is located from coast to coast in the middle of Jut-
land. This population comprise the target group for the
study which has no exclusion criteria.
Randomization
Civil registration numbers and patient data are obtained
from national registries. Randomisation is stratified by
municipalities, as the prevalences of the diseases are
expected to differ in this relatively large region. The
Region consists of 19 counties covering more than 13,000
km2, which includes some of the largest Danish cities in
the eastern part, as well as rural areas in the western part
of the region. The stratification furthermore ensures a
minimum of time span between randomisation and invi-
tation as local screening units individually can report
back to the central randomisation office about their time
schedule.
Person-data are imported to Epidata and Epi-info 6,
where randomisation occurs by giving each subject a ran-
dom number from 1-100, persons with a number above
51 are allocated to the intervention arm i.e. half of sub-
jects are invited to participate in screening and half of
subjects act as controls (as no permanent screening pro-
gramme exists in Denmark).
Outcome
The primary outcome variable is all-cause mortality. The
secondary outcome variables are cardiovascular mortal-
ity, AAA-related mortality, hospital services related to
cardiovascular conditions and costs for such services,
quality of life, and aneurismal progression. Major follow-
up is planned after 3, 5 and 10 years. All-cause mortality,
health care-related costs, cardiovascular and AAA-
related mortality and cardiovascular hospital service are
compared for the two groups.
Analysis of efficacy
Statistical analysis will be performed on an intention to
treat basis. Risk ratios for all-cause mortality, cardiovas-
cular mortality, AAA-related mortality and first cardio-
vascular event in the two groups will be estimated by
Cox-regression. In addition, the numbers of hospital ser-
vices related to cardiovascular conditions will be com-
pared between the two groups by student's t-test. Quality
of life between controls, non-attenders, attenders without
positive finding, and attenderswith AAA or PAD will be
compared at baseline univariately and multivariately
adjusted for age, civil status and co-morbidity, and pro-
spective data from baseline, after 3, 5 and 10 years will be
compared by MANOVA. Aneurysmal progression
(growth rate) will be transformed by the natural loga-
rithm and evaluated in subgroups by univariate and mul-
tivariate linear regression analysis. SPSS 15.0, STATA
12.0 and PEPI will be used for the analysis.
Analysis of cost-effectiveness
The program cost per invited will be estimated using a
micro-costing approach for the intervention (invitations,
screenings, follow up scans). Relevant resource utilization
at hospitals (surgical procedures, admissions, outpatient
visits etc.) will be extracted from the National Patient
Registry and valued using tariffs of the Diagnosis-Related
Grouping (DRG) case-mix system. Participants' time and
transportation costs will be estimated from a prospective
within-sample study of about 1,000 participants using a
questionnaire.
Health-related quality-adjusted life will be estimated
for each individual assuming that baseline quality of life
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[17]. For persons detected with and/or treated for cardio-
vascular disease estimates of decrements in quality of life
will be adapted from the literature and applied.
The net present values of costs, life years gained and
QALYs gained will be compared between randomization
groups [18]. The incremental ratios of costs per life-year
gained and costs per quality-adjusted life year (QALY)
gained will be estimated using nonparametric bootstrap-
ping; for their interpretation the net benefit framework
will be used to present cost-effectiveness acceptability
curves [19,20].
Power and expected benefit
The needed sample size estimation was done by the fol-
lowing assumptions:
The prevalence of AAA and PAD is 4% and 8% respec-
tively. The five year mortality risk in case of AAA or PAD
is 28% oppose to 15% in the control group. Statin-lower-
ing or antiplatelet medication can be initiated in one-
third of the diagnosed men with PAD or AAA and causes
a relative all cause mortality risk reduction of 20%. AAA-
related death within five years is 1% but screening
reduces this with 50%. The expected screening atten-
dance is 75%
If so, the needed sample size is 2 × 23,604 (5% signifi-
cance level and 90% power) and approx. 250 lives will be
saved. If the ten year mortality in the control group is 36%
[3], and if the relative risk is maintained, the needed sam-
ple size is 2 × 7,500, corresponding to 2.5% absolute mor-
tality risk reduction and 590 lives saved corresponding to
40 men needed to screen to prevent one death.
These calculations must be considered to be conserva-
tive and the potential benefit by diagnosing new hyper-
tensives is not included.
Ethical considerations
This trial is approved by the regional scientific ethics
committee and by the national data protection authori-
ties. In accordance with the Clinical Trial Registration
Statement from the International Committee of Medical
Journal Editors, the trial is registered at clinical trials with
the registration number NCT00662480.
Discussion
The study population of men aged 65-74 years has been
selected due to its relatively high cardiovascular risk, as
most studies have reported increased risk with increasing
age and lower prevalences of PAD and AAA in women.
Nonetheless recent studies [21,22] indicates that the inci-
dence of PAD in women is also considerable especially
among elder women. Data on the prevalence and progno-
sis in woman are however too sparse at the moment to
justify a parallel randomised trial but indeed it may be
relevant to include women in a later stage, especially if
the existing trial proves to be cost effective.
Conclusions
The VIVA screening trial is a prospective randomized
clinical trial examining the efficacy and cost effectiveness
of a screening programme for early detection of AAA and
PAD across 50,000 men aged 65-74 years. The primary
outcome is all-cause mortality and secondary outcomes
are AAA-related mortality, costs of hospital services
related to cardiovascular conditions, quality of life, aneu-
rismal progression and cost-effectiveness. Upon evalua-
tion of outcome parameters after 3, 5, 10 and 15 years,
this study will inform policy-makers about the attractive-
ness of introducing a national, permanent screening pro-
gramme for cardiovascular disease
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